KESTREL and KITE: 52-week results from two Phase III pivotal trials of brolucizumab for diabetic macular edema

Published 2022 View Full Article

  1. Home
  2. Publications
  3. Publication Search
  4. Publication Details
Title
KESTREL and KITE: 52-week results from two Phase III pivotal trials of brolucizumab for diabetic macular edema
Authors
Keywords
Aflibercept, anti-VEGF, brolucizumab, diabetic macular edema, q12w
Journal
AMERICAN JOURNAL OF OPHTHALMOLOGY
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2022-01-14
DOI
10.1016/j.ajo.2022.01.004

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Reprint

Contact the author

Find Funding. Review Successful Grants.

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Discover Peeref hubs

Discuss science. Find collaborators. Network.

Join a conversation
Webinars Posters Questions Hubs Funding Journals Articles Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.